KINÁZOVÉ INHIBITORY A JEJICH NEJBĚŽNĚJŠÍ FARMAKOKINETICKÉ INTERAKCE
| Title in English | KINASE INHIBITORS AND THEIR MOST COMMON PHARMACOKINETIC INTERACTIONS |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Chapter of a book |
| MU Faculty or unit | |
| Citation | |
| Description | Inhibition of a kinase, which is part of a signaling pathway in the cell, affects the transcription or translation of genes and can stop cell growth, proliferation or metabolism. The effectiveness of kinase inhibitors is influenced by several factors. Signalling pathways in cells are very complex and knocking out one protein can lead to the use of an alternative signalling pathway. However, some molecules act at multiple sites by inhibiting several proteins and limit the use of alternative pathways. The target protein may also be mutated in such a way that the drug molecule does not act on it. Such an occurrence resistance can occur during treatment or during relapse. Molecular genetic testing of tumour tissue can provide information about which signalling pathways the tumour cell used, if specific mutations are present in the kinases and what treatments might be effective. In a number of cases, this examination is a condition for reimbursement from public health insurance (this is discussed in the previous chapters for individual diagnoses). In the case of rare tumours or tumours of unknown origin, molecular genetic testing can help to indicate effective treatment. An overview of kinase receptor inhibitors registered in the Czech Republic and their target structures is given in the following chapter. |
| Related projects: |